findmyKOL

Rami Komrokji, MD

Enriched profile

Professor; Vice Chair, Malignant Hematology Department; Section Head, Leukemia and MDS; Senior Member, Malignant Hematology and Experimental Therapeutics Program (also described as Clinical Director, Malignant Hematology Department, per AAMDSIF bio) · H. Lee Moffitt Cancer Center and Research Institute

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Tampa, FL · Southeast · United StatesSpecialtyHematologyFocusAcute Myeloid Leukemia Research+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Rami Komrokji is Professor; Vice Chair, Malignant Hematology Department; Section Head, Leukemia and MDS; Senior Member, Malignant Hematology and Experimental Therapeutics Program (also described as Clinical Director, Malignant Hematology Department, per AAMDSIF bio) at H. Lee Moffitt Cancer Center and Research Institute. OpenAlex indexes 1,527 publications with 19,045 citations (h-index 69); ClinicalTrials.gov lists 14 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 16 Oct 2026

Rami S. Komrokji, M.D., is Professor at H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. The public record shows 1,527 publications with 19,045 citations (h-index 69), centered on Acute Myeloid Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 40 companies.

  • Most recent indexed publication: 2026 · Blood
  • Top research focus: Acute Myeloid Leukemia Research
  • 14 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 40 companies

Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
MDS / MPN9 trialsLeukemia (AML/ALL/CML/CLL)5 trialsLeukemia, Myeloid, Acute3 trialsMyeloproliferative Disorders1 trialPrimary Myelofibrosis1 trialPolycythemia Vera1 trialThrombocythemia, Essential1 trialThrombocytosis1 trialPolycythemia1 trialRecurrence1 trialThrombocytopenia1 trialCytopenia1 trialBlast Crisis1 trial

Research focus

OpenAlex concept fingerprint
Acute Myeloid Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and TreatmentChronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia ResearchHemoglobinopathies and Related Disorders

Drugs & molecules

across trials, industry payments and publications
Vonjogeneric · PacritinibClinical trials1Industry payments58Publications1Venclextageneric · VenetoclaxClinical trials2Industry payments41Publications8Reblozylgeneric · LuspaterceptClinical trials1Industry payments15Publications10LenalidomideClinical trials1Industry payments14Publications3Rytelogeneric · ImetelstatClinical trials—Industry payments20Publications6AzacitidineClinical trials1Industry payments—Publications12DecitabineClinical trials1Industry payments—Publications1Besremigeneric · Ropeginterferon alfa-2bClinical trials—Industry payments59Publications—Vyxeosgeneric · Cytarabine / daunorubicinClinical trials—Industry payments50Publications—Rezlidhiageneric · OlutasidenibClinical trials—Industry payments48Publications—Tavalissegeneric · FostamatinibClinical trials—Industry payments43Publications—Tibsovogeneric · IvosidenibClinical trials—Industry payments38Publications—

Works with

trial sponsors and companies reporting payments
PharmaEssentia USA CorporationClinical trials—Industry payments59Jazz Pharmaceuticals Inc.Clinical trials—Industry payments51Rigel Pharmaceuticals, Inc.Clinical trials—Industry payments48Servier Pharmaceuticals LLCClinical trials—Industry payments38Sobi, IncClinical trials—Industry payments37Celgene CorporationClinical trials—Industry payments27Abbvie Inc.Clinical trials—Industry payments25Genentech USA, Inc.Clinical trials—Industry payments23CTI BioPharma Corp.Clinical trials—Industry payments21Hikma Pharmaceuticals USAClinical trials—Industry payments21Geron CorporationClinical trials—Industry payments20E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments16Syndax Pharmaceuticals, Inc.Clinical trials—Industry payments14Daiichi Sankyo Inc.Clinical trials—Industry payments12H. Lee Moffitt Cancer Center and Research InstituteClinical trials8Industry payments—Novartis Pharmaceuticals CorporationClinical trials—Industry payments7Taiho Oncology, Inc.Clinical trials—Industry payments7Stemline Therapeutics Inc.Clinical trials—Industry payments6GlaxoSmithKline, LLC.Clinical trials—Industry payments4Sumitomo Pharma America, Inc.Clinical trials—Industry payments4Takeda Pharmaceuticals U.S.A., Inc.Clinical trials—Industry payments4Astellas Pharma US IncClinical trials—Industry payments2Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments2Acceleron Pharma, Inc.Clinical trials—Industry payments1Alexion Pharmaceuticals, Inc.Clinical trials—Industry payments1AstraZeneca Pharmaceuticals LPClinical trials—Industry payments1Blueprint Medicines CorporationClinical trials—Industry payments1Boehringer Ingelheim International GmbHClinical trials—Industry payments1Eleos, Inc.Clinical trials1Industry payments—Foundation Medicine, Inc.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,527publications

Distinct works indexed by OpenAlex, matched via ORCID; 97 in PubMed.

19,045citations

Total citations across indexed works.

69h-index

Hirsch index (OpenAlex). i10-index 330.

Clinical & industry

trials, payments and federal funding
14clinical trials

Investigator role on registered studies.

View trials ↓
40companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 16 Oct 2026

Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:

All 14 trial records: search, sort and filter.Explore →

Industry payments

Updated 16 Oct 2026

40 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 78 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    67.5%
    Kinase inhibitor15.9%
    Vanflyta54%Vonjo46%
    Part D<11 patients
    Janus-associated kinase (JAK) inhibitors12.6%
    Ojjaara100%
    Part D<11 patients

    + 4 more classes in this area

  • Musculoskeletal

    13.2%
    Xanthine oxidase inhibitor13.2%
    Allopurinol100%
    Part D≥12 patients

  • Nervous system

    10.6%
    Opioid Agonist10.6%
    Oxycodone Hcl100%
    Part D<11 patients
All 4 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)73.8% facility · 26.2% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 16 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 97 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
    538 citations2020
    doi.org ↗
  2. 02
    Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic Syndromes
    460 citations2021
    doi.org ↗
  3. 03
    The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype
    346 citations2016
    doi.org ↗
  4. 04
    Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
    336 citations2014
    doi.org ↗
  5. 05
    A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
    334 citations2017
    doi.org ↗
All 1,527 cited works: search, sort and filter.Explore →

Network

Updated 16 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Eric Padron708Jeffrey E. Lancet646David A. Sallman593Andrew Kuykendall422Alan F. List410Mikkael A. Sekeres305Onyee Chan272Kendra Sweet253Najla Al Ali245Guillermo Garcia‐Manero208Amy E. DeZern174Valeria Santini171Amer M. Zeidan164Pierre Fenaux161Uwe Platzbecker160Maria E. Balasis154Najla H. Al Ali152Gail J. Roboz150David P. Steensma145Mrinal M. Patnaik139Seongseok Yun138Zhuoer Xie137Aaron T. Gerds135John Mascarenhas132Alessandro M. Vannucchi131Hannah Newman128Markus Ball128Ruben A. Mesa127Traci Kruer127Christopher T. Letson124Somedeb Ball116Michael R. Savona114Raajit K. Rampal111Marina Kremyanskaya107Terra L. Lasho106Ronald Hoffman105Moshe Talpaz103Jeanne Palmer103Christy M. Finke103Ling Zhang103

Online presence

Updated 16 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/rami-komrokji-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
  • LinkedIn

    linkedin.com/in/rami-komrokji-7b952047

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
  • ResearchGate

    researchgate.net/profile/Rami-Komrokji

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
  • X / Twitter

    x.com/Ramikomrokji

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com ↗
  • Google Scholar

    scholar.google.com/citations

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →scholar.google.com ↗

Mentions by others

where others cite or feature them
  • Facebook

    facebook.com/OncLive/videos/hear-rami-komrokji-md-of-moffitt-cancer-center-discuss-several-trials-that-suppo/1213350000430808

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗
  • Other

    onclive.com/authors/rami-d-komrokji-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
  • YouTube

    youtube.com/watch

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
  • X / Twitter

    Twitter/X handle @ramikomrokji (professional account referencing Moffitt/hematology-oncology work, corroborated via two independent SERP passes and third-party naming by a fellow hematologist at ASH24)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
  • Google Scholar

    Google Scholar author profile (a3Q5XbYAAAAJ), listing MDS/AML/MPN publication record consistent with Moffitt affiliation

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →scholar.google.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 16 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • M.D.

    Jordan University School of Medicine, Amman, Jordan

    1996
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →iononline.com ↗
  • Internship and Residency

    Internal Medicine, Case Western Reserve University, St. Vincent Program, Cleveland, OH

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →iononline.com ↗
  • Fellowship

    Hematology/Oncology and Hematopoietic Stem Cell Transplantation, Strong Memorial Hospital, University of Rochester, Rochester, NY

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →iononline.com ↗
  • Board certified

    Hematology (Internal Medicine, Hematology taxonomy 207RH0000X, FL)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →npiregistry.cms.hhs.gov ↗

Editorial & leadership roles

journal and society appointments
  • Vice Chair

    Malignant Hematology Department, Moffitt Cancer Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
  • Section Head

    Leukemia and MDS, Moffitt Cancer Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
  • Senior Member

    Malignant Hematology and Experimental Therapeutics Program, Moffitt Cancer Center

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →iononline.com ↗
  • Member

    Medical Advisory Board, Aplastic Anemia and MDS International Foundation (AAMDSIF)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗
  • Clinical Director

    Malignant Hematology Department; Lead Clinical Investigator, MDS Program (per AAMDSIF bio; alternate title framing from an independent secondary source, not fully reconciled with Moffitt-sourced title)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →aamds.org ↗
  • Reported: member

    NCCN MDS Panel; member, NHLBI MDS natural history study steering committee (recurring across multiple independent secondary bios, e.g. WebSearch synthesis of Moffitt/ResearchGate content) …

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Professor

    Medicine & Oncologic Sciences, University of South Florida College of Medicine, Tampa, FL (joint academic appointment)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →patientpower.info ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.